Drugs / PPSGG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04568174 Comparator | Nov 2020 → Sep 2021 | polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG | Polyneuron Pharmaceuticals AG | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPSGG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04568174 ↗ |